



3 Information Groups by Area




3.6 Surgery, Transplant and Health Technologies Area

1 Introduction

2 Executive Summary

3 Information Groups by Area

4 Associated Clinicians



3.6.2 Cellular Engineering Group

Publications: 9

Q1: 3

COMPOSITION


María Paz de Miguel González. Investigadora Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. FIBHULP

Marta Cadenas Martín. Investigador Predoctoral. FIBHULP

María Pilar González-Peramato Gutiérrez. Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz

Manuel Nistal Martín de Serrano. Catedrático Departamento de Histología y Neurociencia. Facultativo de Medicina. Universidad Autónoma de Madrid

Javier Francisco Regadera González. Catedrático. Departamento de Histología y Neurociencia. Facultad de Medicina. Universidad Autónoma de Madrid



STRATEGIC OBJECTIVE

To ascertain the mechanisms responsible for converting a differentiated cell into a pluripotent cell and at the same time how these establish a relationship between cellular reprogramming and oncogenic transformation, in order to use divergent pathways governing these processes as clinical early diagnostic tools and therapeutic targets for clinical intervention.

To develop new cell therapy approaches in diverse organs transplants.

RESEARCH LINES

- Molecular mechanisms of cellular reprogramming in normal and neoplastic environments.
- New techniques and therapies in transplants.



3 Information Groups by Area



3.6 Surgery, Transplant and Health Technologies Area

RESEARCH ACTIVITY

● Doctoral theses

● Master Theses

Linzoain Agos P. Generation of human limbal cells for use in ophthalmology [dissertation]. Madrid: UAM; 2022(15/06/2022).

Director: de Miguel MP.

● Publications

- Albiñana V, Recio-Poveda L, González-Peramato P, Martínez-Pineiro L, Botella LM, Cuesta AM. Blockade of beta 2-adrenergic receptor reduces inflammation and oxidative stress in clear cell renal cell carcinoma. *Int J Mol Sci.* 2022; 23(3): 1325. Article. IF: 5.6; Q1

- Bernardini A, Dueñas M, Martín-Soberón MC, Rubio C, Suárez-Cabrera C, Ruiz-Palomares R, Munera-Maravilla E, Lázaro S, Lodewijk I, Rueda D, Gómez-Sánchez D, Alonso-Gordoa T, Puente J, Pinto A, González-Peramato P, Aguado C, Herrera M, López F, Martínez VMG, Morales L, Castellano D, Paramio JM, de Velasco G. Genomic landscape of vinflunine response in metastatic urothelial cancer. *Cancers (Basel).* 2022; 14(2): 378. Article. IF: 5.2; Q2
- de la Parra I, Serrano A, Vives R, Hermida J, Díez-Valladares LI, Barrera J, Cortes JA, González-Peramato P, Gómez A, Moreno J. Sarcomatoid transformation of chromophobe renal cell carcinoma: an unusual pathology. *Eurasian J Med Oncol.* 2022; 6(2): 192-3. Letter. IF: 2.5; Q2
- del Barrio JLA, de la Mata A, de Miguel MP, Arnalich-Montiel F, Nieto-Miguel T, El Zarif M, Cadenas-Martín M, López-Paniagua M, Galindo S, Calonge M, Alio JL. Corneal regeneration using adipose-derived mesenchymal stem cells. *Cells.* 2022; 11(16): 2549. Review. IF: 6; Q2
- González-del-Alba A, Conde-Moreno AJ, Vicente AGM, González-Peramato P, Linares-Espinós E, Climent MA. Management of patients with metastatic bladder

cancer in the real-world setting from the multidisciplinary team: current opinion of the SO-GUG Multidisciplinary Working Group. *Cancers (Basel).* 2022; 14(5): 1130. Article. IF: 5.2; Q2

- Guerrero-Fernández J, González-Peramato P, Estévez AR, Villar MJA, Parera LA, San Julián MCA, Urqui AC, González LAC, Tello JMM, Palma CM, Macian MFM, Fernández DY, Nistal M. Consensus guide on prophylactic gonadectomy in different sex development. *Endocrinol Diabetes Nutr.* 2022; 69(8): 629-45. Article. IF: 1.9; Q4
- Ramos-Levi A, Barabash A, Valerio J, de la Torre NG, Mendizábal L, Zulueta M, de Miguel MP, Díaz A, Duran A, Familiar C, Jiménez I, del Valle L, Melero V, Moraga I, Herráiz MA, Torrejón MJ, Arregi M, Simón L, Rubio MA, Calle-Pascual AL. Genetic variants for prediction of gestational diabetes mellitus and modulation of susceptibility by a nutritional intervention based on a Mediterranean diet. *Front Endocrinol (Lausanne).* 2022; 13: 1036088. Article. IF: 5.2; Q1
- Rodríguez-Muñoz D, Sánchez A, Pérez-Benavente S, Contreras-Jurado C, Montero-Pedrazuela A, Toledo-Castillo M, Gutiérrez-Hernández M, Rodrigues-Díez R, Folgueira C, Briones AM, Sábio G, Monedero-Cobeta I, Chavez-Coira I, Castejón D, Fernández-Valle E, Regadera J, Bautista JM, Aranda A, Alemany S. Hypothyroidism confers tolerance to cerebral malaria. *Sci Adv.* 2022; 8(14): eabj7110. Article. IF: 13.6; D1
- Zamora JM, de Dicastill BPML, Nistal MG, Rodríguez NAC, Angulo JDZ, Turegano BM, Heredero AF. Outcomes and prosthesis procedure of major amputations in patients with peripheral arterial disease in our center. *Angiologia.* 2022; 74(6): 278-85. Article. IF: 0.1; Q4

● Research projects

Cadenas Martín M. Contrato predoctoral (PE-JD-2018-PRE/BMD-8878). CM. 2019-2021.

Management centre: FIBHULP

de Miguel González MP. Bio-Ingeniería de tejido corneal para trasplante endotelial: de-

sarrollo de láminas ultrafinas de cornea descelularizada colonizadas por endoletio corneal humano expandido en cultivo. Roche Farma S.A. 2016-Ongoing.

Management centre: FIBHULP

de Miguel González MP. Contrato Miguel Servet Categoría A (CP03/0007). CM. 2010-2025.

Management centre: FIBHULP

de Miguel González MP. Contribución de la modificación metabólica a la reprogramación celular y la transformación onco génica. Fundación Domingo Martínez. 2017-Ongoing.

Management centre: FIBHULP

de Miguel González MP. Generación de estroma corneal bio-mimético por impresión 3D de colágeno y células madre mesenquimales. Stem Vision S. L. 2021-Ongoing.

Management centre: FIBHULP

● Patents and trademarks

de Miguel González MP, Arnalich Montiel F, Royuela MM, inventors; FIBHULP, Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, Universidad de Alcalá, assignees. Corneal endothelium injector; P201131222, PCT/ES2012/070543; 2011 July 18.

de Miguel González MP, Arnalich-Montiel F, Cadenas Martín M, Moratilla Riofrío A. inventors; FIBHULP, FIBHRYC, assignees. Constructos artificiales para su uso en oftalmología, su procedimiento de obtención y utilización del mismo. Patente Europea EP22382119.0 2022 February 14. PCT/EP2023/053668 2023 February 14.

